Texas AG sues Pfizer over quality-control lapses in kids’ ADHD drug

 ADHD in the News 2023-11-30


Nov 20 (Reuters) - Texas Attorney General Ken Paxton accused Pfizer (PFE.N) and its supplier Tris Pharma of providing children's ADHD medicine that it knew might be ineffective to the state's Medicaid insurance program for low-income people, in a lawsuit unsealed on Monday.

View Article: Reuters, November 21, 2023




Other Articles in this Edition

Shortage of Adderall and other ADHD drugs expected to last through 2024, despite federal attempts to fix it

Longer Use of ADHD Meds May Boost Heart Risk — Observational data suggest particular risk for hypertension and arterial disease

People taking ADHD medications should closely monitor their heart health, study suggests

Understanding subjective beliefs could be vital to tailoring more effective treatments for depression and ADHD

Deep-Learning Model Shows Promise for ADHD Diagnosis in Teens — AI algorithm identified significant differences in nine brain white matter tracts

Psychiatric Comorbidity Increases Risk for Schizophrenia With ADHD

New study sheds light on ADHD’s impact on motivation and the efficacy of amphetamine-based meds

Microdosing psychedelics shows promise for improving mindfulness in adults with ADHD

Texas AG sues Pfizer over quality-control lapses in kids’ ADHD drug

US Limit on a Key ADHD Drug Is Worsening Shortages, Group Says

WHO issues new and updated recommendations on treatment of mental, neurological and substance use conditions

Diagnosed With ADHD — What Should I Do Now?

What it’s like to be diagnosed with ADHD as an adult in China